




# Learning Objectives

- Anatomy of the breast
- Breast cancer statistics
- TNM staging
- Surgical procedures and coding
- $_{\circ}$  AJCC  $8^{\text{th}}$  edition Staging for Breast Cancer






Anatomy of the Breast



Anatomy of the Breast





Anatomy of the Lymph Nodes




### **Statistics**

- Louisiana has the 33rd highest incidence and second highest death (mortality) rate of breast cancer in the U.S.
  - $\circ\,$  123.4 people per 100,000 were diagnosed with breast cancer, while the national average was 125.0 per 100,000.
  - $^\circ$  An average of 24.5 Louisiana residents per 100,000 died each year from this disease, while the national average was 21.5 deaths per 100,000.
- Breast cancer is an equal-opportunity killer, with Louisiana white women are slightly below the national death rate while black women are significantly higher than the rest of the country.









### Staging Classifications - Time Points of Staging

#### Clinical

- Before initiation of treatment: prefix "c" cT, cN
- All information from history, physical examination and imaging
- Whatever is available advanced imaging NOT required

#### Pathological

- Clinical information
- PLUS results of surgery (if surgery initial treatment): prefix pT, pN

#### Prognostic

- Anatomic T, N, M plus relevant non-anatomic factors (e.g. grade, HER2, ER, PR)


### Post-therapy (post-neoadjuvant)


 Clinical or pathologic information after completion of systemic or radiation therapy if this treatment precedes / replaces surgery: prefix ypT; ypN

#### · Less Commonly Used:


- Recurrent Extent of disease at recurrence: prefix rT, rN
- Autopsy For cancer identified only at autopsy

## T - Tumor Size





## T - Tumor Size




### T - Tumor Size

### • T4d – Inflammatory Breast cancer


- A clinical-pathological entity characterized by diffuse erythema and edema (peau d'orange) involving a third or more of the skin of the breast.
- Primarily a clinical diagnosis.
- Must have a tissue diagnosis of breast cancer from the breast parenchyma but skin punch biopsy may be negative for tumor in the dermal lymphatics.


## N - Nodal Status - Clinical





## N – Nodal Status - Pathological

























### M – Distant Metastasis


- Based on clinical exam
  - Must include history and physical exam and appropriate imaging
  - Biopsy conformation is done when feasible.
  - The classification of M1 continues even when there is no evidence of disease after treatment.













# Quadrantectomy




# Simple Mastectomy






# Modified Radical Mastectomy











# Changes in the 8th edition

- The addition of Prognostic Stage Groups
- LCIS no longer included as it is benign
- ∘Tumors <1mm are not rounded to nearest mm. Tumors >1 and <2mm are rounded to 2mm
- Multiple tumors are based on largest tumor and designated by an "m" – example T1b(m)

# Changes in the 8th edition

- Complete pathologic response is no residual invasive tumor, may have residual non-invasive, fibrosis does not count as residual disease
- Inclusion of receptors (ER, PR, HER2), grade, and multigene panels (Oncotype, Mammaprint)

When T is	And N is	And M is	Then the stage group is
Tis	N0	M0	0
T1	N0	M0	IA
T0	N1mi	M0	IB
T1	N1mi	M0	IB
T0	N1	M0	IIA
T1	N1	M0	IIA
T2	N0	M0	IIA
T2	N1	M0	IIB
T3	N0	M0	IIB
T0	N2	M0	IIIA
T1	N2	M0	IIIA
T2	N2	M0	IIIA
T3	N1	M0	IIIA
T3	N2	M0	IIIA
T4	N0	M0	IIIB
T4	N1	M0	IIIB
T4	N2	M0	IIIB
Any T	N3	M0	IIIC
Any T	Any N	M1	IV



When T is	And N is	And M is	And G is	And HER2 Status* is	And ER Status is	And PR Status is	Then the Prognostic Stage Group is
Tis	N0	MO	1-3	Any	Any	Any	0
T1	N0	M0	1	Positive	Any	Any	IA
T1	N0	MO	1-2	Negative	Positive	Positive	IA
T1	N0	MO	2	Positive	Positive	Positive	IA
T1	N0	M0	3	Positive	Positive	Any	IA
T0-1	N1mi	M0	1	Positive	Any	Any	IA
T0-1	N1mi	MO	1-2	Negative	Positive	Positive	IA
T0-1	N1mi	MO	2	Positive	Positive	Positive	IA
T0-1	N1mi	MO	3	Positive	Positive	Any	IA
MultiGana Pan	el** Oncotyn	e Dx® Recurrenc	a Scora Lace Th	on 11			
T1-2	N0	M0	1-3	Negative	Positive	Any	IA
11-2	NO THE RESERVE OF THE PERSON NAMED IN COLUMN TO THE PERSON NAMED I	IVIO	NAME OF TAXABLE PARTY.	regative	Tositive	Amy	
TI	N0	МО	1	Negative	Positive	Negative	IB
TI	N0	MO	1	Negative	Negative	Positive	IB
TI	N0	MO	2	Positive	Positive	Negative	IB
T1	N0	MO	2	Positive	Negative	Any	IB
TI	N0	MO	2	Negative	Negative	Positive	IB
TI	N0	MO	3	Positive	Negative	Any	IB
TI	N0	M0	3	Negative	Positive	Positive	IB
T0-1	N1mi	MO	1	Negative	Positive	Negative	IB
T0-1	N1mi	MO	i	Negative	Negative	Positive	IB
T0-1	N1mi	MO	2	Positive	Positive	Negative	IB
T0-1	N1mi	MO	2	Positive	Negative	Any	IB
T0-1	N1mi	MO	2	Negative	Negative	Positive	IB
T0-1	N1mi	MO	3	Positive	Negative	Any	IB
T0-1	N1mi	M0	3	Negative	Positive	Positive	IB
T2	N0	MO	1-3	Positive	Positive	Positive	IB
T2	N0	M0	1,2	Negative	Positive	Positive	IB
TI	N1	MO	1-3	Positive	Positive	Positive	IB
Ti	N1	M0	1-2	Negative	Positive	Positive	IB
T2	NI	MO	1	Negative	Positive	Positive	IB***
T2	N1	M0	2	Positive	Positive	Positive	IB***
T0-2	N2	МО	1-2	Positive	Positive	Positive	IB***



When T is	And N is	And M is	And G is	And HER2 Status* is	And ER Status is	And PR Status is	Then the Prognostic Stage Group is
T3	N1-2	M0	1	Positive	Positive	Positive	IB***
T3	N1-2	M0	2	Positive	Positive	Positive	IB***
							***
T1	N0	M0	1	Negative	Negative	Negative	IIA***
T1	N0	M0	2	Negative	Negative	Negative	IIA***
T1	N0	M0	3	Negative	Positive	Negative	ПА***
T1	N0	M0	3	Negative	Negative	Positive	IIA***
T1	N0	M0	3	Negative	Negative	Negative	IIA***
T0-1	N1mi	M0	1	Negative	Negative	Negative	IIA
T0-1	N1mi	MO	2	Negative	Negative	Negative	IIA
T0-1	N1mi	M0	3	Negative	Positive	Negative	IIA
T0-1	N1mi	M0	3	Negative	Negative	Positive	IIA
T0-1	Nlmi	M0	3	Negative	Negative	Negative	IIA
T0-1	N1	M0	1	Positive	Positive	Negative	IIA
T0-1	NI	MO	1 - 2	Positive	Negative	Any	IIA
T0-1	N1	M0	1	Negative	Positive	Negative	IIA
T0-1	N1	M0	1	Negative	Negative	Positive	IIA
T0-1	N1	M0	3	Negative	Positive	Positive	IIA
T2	N0	M0	1	Positive	Positive	Negative	IIA
T2	N0	M0	1 - 2	Positive	Negative	Any	IIA
T2	N0	M0	1	Negative	Positive	Negative	IIA
T2	N0	M0	1	Negative	Negative	Positive	IIA
T2	N0	M0	3	Negative	Positive	Positive	IIA
T0-2	N2	M0	1	Negative	Positive	Positive	IIA***
Т3	N1-2	M0	1	Negative	Positive	Positive	IIA

Prognostic Staging

T0-1	N1	M0	1	Negative	Negative	Negative	IIB
T0-1	N1	MO	2	Positive	Positive	Negative	IIB
T0-1	NI	M0	2	Negative	Positive	Negative	IIB
T0-1	N1	M0	2	Negative	Negative	Positive	IIB
T0-1	N1	M0	3	Positive	Positive	Negative	IIB
T0-1	NI	M0	3	Positive	Negative	Any	IIB
T2	N0	M0	1	Negative	Negative	Negative	IIB
T2	N0	M0	2	Positive	Positive	Negative	IIB
T2	N0	M0	2	Negative	Positive	Negative	IIB
T2	N0	M0	2	Negative	Negative	Positive	IIB
T2	N0	M0	3	Positive	Positive	Negative	IIB
T2	N0	M0	3	Positive	Negative	Any	IIB
T2	NI	M0	1	Positive	Any	Any	IIB
T2	N1	M0	1	Negative	Negative	Positive	ПВ
T0-2	N2	M0	2	Negative	Positive	Positive	IIB
T0-2	N2	M0	3	Positive	Positive	Positive	IIB
Т3	N1-2	M0	2	Negative	Positive	Positive	IIB
Т3	N1-2	M0	3	Positive	Positive	Positive	IIB
T0-1	N1	M0	2	Negative	Negative	Negative	IIIA***
T0-1	N1	M0	3	Negative	Positive	Negative	IIIA

### Prognostic Staging

When T is	And N is	And M is	And G is	And HER2 Status* is	And ER Status is	And PR Status is	Then the Prognostic Stage Group is
T0-1	NI	M0	3	Negative	Negative	Any	IIIA
T2	N0	M0	2	Negative	Negative	Negative	IIIA***
T2	N0	M0	3	Negative	Positive	Negative	IIIA***
T2	N0	M0	3	Negative	Negative	Any	IIIA***
T2	N1	M0	1	Negative	Positive	Negative	IIIA
T2	NI	M0	2	Positive	Negative	Negative	IIIA
T2	N1	MO	2	Negative	Positive	Negative	IIIA
T2	N1	M0	3	Positive	Positive	Negative	IIIA
T2	N1	M0	3	Positive	Negative	Negative	IIIA
Т3	N0	M0	1	Negative	Positive	Negative	IIIA
Т3	N0	M0	2	Positive	Negative	Negative	IIIA
Т3	N0	M0	2	Negative	Positive	Negative	IIIA
Т3	N0	MO	3	Positive	Positive	Negative	IIIA
Т3	N0	M0	3	Positive	Negative	Negative	IIIA
T0-2	N2	M0	1	Positive	Positive	Negative	IIIA
T0-2	N2	MO	1	Positive	Negative	Any	IIIA
T0-2	N2	MO	1	Negative	Positive	Negative	IIIA
T0-2	N2	M0	1	Negative	Negative	Positive	IIIA
T0-2	N2	M0	2	Positive	Positive	Negative	IIIA
T0-2	N2	M0	2	Positive	Negative	Any	IIIA
Т3	N1-2	M0	1	Positive	Positive	Negative	IIIA
T3	N1-2	M0	1	Positive	Negative	Any	IIIA
Т3	N1-2	M0	1	Negative	Positive	Negative	IIIA
T3	N1-2	M0	1	Negative	Negative	Positive	IIIA
T3	N1-2	M0	2	Positive	Positive	Negative	IIIA
Т3	N1-2	M0	2	Positive	Negative	Any	IIIA
T4	N0-2	M0	1	Negative	Positive	Positive	ША
Any	N3	M0	1	Negative	Positive	Positive	IIIA***

### Prognostic Staging

266 537 638 638 638 638			225300000000000000000000000000000000000		0.500 Mark 10.000 Mark 10.		
T2	N1	M0	1 - 2	Negative	Negative	Negative	IIIB***
T2	NI	M0	3	Negative	Positive	Negative	IIIB***
							****
T3	N0	M0	1 - 2	Negative	Negative	Negative	IIIB
T3	N0	M0	3	Negative	Positive	Negative	IIIB
T0-2	N2	M0	2	Negative	Positive	Negative	IIIB
T0-2	N2	M0	2	Negative	Negative	Positive	IIIB
T0-2	N2	M0	. 3	Positive	Positive	Negative	IIIB
T0-2	N2	M0	3	Positive	Negative	Any	IIIB
T0-2	N2	M0	3	Negative	Positive	Positive	IIIB
Т3	N1-2	M0	2	Negative	Positive	Negative	IIIB
T3	N1-2	M0	2	Negative	Negative	Positive	IIIB
Т3	N1-2	M0	3	Positive	Positive	Negative	IIIB
Т3	N1-2	M0	3	Positive	Negative	Any	IIIB
Т3	N1-2	M0	3	Negative	Positive	Positive	IIIB
T4	N0-2	M0	1	Positive	Any	Any	ШВ
T4	N0-2	M0	2	Positive	Positive	Positive	IIIB

### Prognostic Staging

When T is	And N is	And M is	And G is	And HER2	And ER	And PR Status	Then the Prognostic
				Status* is	Status is	is	Stage Group is
T4	N0-2	M0	2	Negative	Positive	Positive	IIIB
T4	N0-2	M0	3	Positive	Positive	Positive	IIIB
Any	N3	M0	1	Positive	Any	Any	IIIB
Any	N3	M0	2	Positive	Positive	Positive	IIIB
Any	N3	M0	2	Negative	Positive	Positive	IIIB
Any	N3	M0	3	Positive	Positive	Positive	IIIB
T2	NI	M0	3	Negative	Negative	Any	IIIC***
					-		
T3	N0	M0	3	Negative	Negative	Any	IIIC
T0-2	N2	M0	2	Negative	Negative	Negative	IIIC***
T0-2	N2	M0	3	Negative	Positive	Negative	IIICees
T0-2	N2	M0	3	Negative	Negative	Any	IIIC***
T3	N1-2	M0	2	Negative	Negative	Negative	IIIC***
T3	N1-2	M0	3	Negative	Positive	Negative	IIIC***
T3	N1-2	M0	3	Negative	Negative	Any	IIIC***
T4	N0-2	M0	1	Negative	Positive	Negative	IIIC
T4	N0-2	M0	1	Negative	Negative	Any	IIIC
T4	N0-2	M0	2	Positive	Positive	Negative	IIIC
T4	N0-2	M0	2	Positive	Negative	Any	IIIC
T4	N0-2	M0	2	Negative	Positive	Negative	IIIC
T4	N0-2	M0	2	Negative	Negative	Any	IIIC
T4	N0-2	M0	3	Positive	Positive	Negative	IIIC
T4	N0-2	M0	3	Positive	Negative	Any	IIIC
T4	N0-2	M0	3	Negative	Any	Any	IIIC
Any	N3	M0	1	Negative	Positive	Negative	IIIC
Any	N3	M0	1	Negative	Negative	Any	IIIC
Any	N3	M0	2	Positive	Positive	Negative	IIIC
Any	N3	M0	2	Positive	Negative	Any	IIIC
Any	N3	M0	2	Negative	Positive	Negative	IIIC
Any	N3	M0	2	Negative	Negative	Any	IIIC
Any	N3	M0	3	Positive	Positive	Negative	IIIC
Any	N3	M0	3	Positive	Negative	Any	IIIC
Any	N3	M0	3	Negative	Any	Any	IIIC
AnyT	AnyN	MI	1-3	Any	Any	Any	IV



# Major changes in Stage Groups from Anatomic Staging for Many Situations - Examples

	TNM		Biomarkers			Genomic Profile	Stage	Groups	
<b>T</b>	N	M	Grade	HER2	ER	PR	Oncotype Dx	7 <sup>th</sup> Edition Anatomic	8th Edition Prognostic
1	0	0	1	Neg	Neg	Neg	N/A	IA	IIA
3	1-2	0	1	Pos	Pos	Pos	N/A	IIIA	IB
0-2	2	0	1-2	Pos	Pos	Pos	N/A	IIIA	IB
2	0	0	Any	Neg	Pos	Any	< 11	IIA	IA

## Registry Data Collection Variables

- ER: positive versus negative; percent positive; Allred score, if available
- PR: positive versus negative; percent positive; Allred score, if available
- ∘ HER2 IHC: 0, 1+, 2+, 3+; or unknown or not performed
- HER2 FISH: negative, positive; HER2:CEP17 ratio; and HER2 copy number, if available; or unknown or not performed

### Registry Data Collection Variables

- HER2: Overall result, negative, positive, unknown if done; not performed
- Nottingham histologic grade: low (1), intermediate (2), high(3)
- Ki-67, if available: percent positive
- Oncotype Dx® recurrence score (numeric score preferred over risk level)
- Oncotype DX ® DCIS recurrence score (numeric score preferred over risk level)

## Registry Data Collection Variables

- Mammaprint® (numeric score preferred over risk level)
- PAM50 intrinsic subtypes and Risk of Recurrence score (ProSigna) (numeric score preferred over risk level)
- Breast Cancer Index (numeric score preferred over risk level)
- EndoPredict (numeric score preferred over risk level)
- IHC4 (numeric score preferred over risk level)

## Registry Data Collection Variables

- Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1)<sup>101</sup>
- Response to treatment: CR, PR, NR